 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
59 News |  |
| 12» |
- ||| lodapolimab (LY3300054) / Eli Lilly
Trial completion, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Sep 26, 2024
P1, N=164, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed
- | LY3200882 / Eli Lilly
Trial completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Jun 25, 2024
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Trial completion date: Aug 2024 --> Aug 2025
- | lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Apr 19, 2024
P1, N=215, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Aug 2024 --> Aug 2025 Trial completion date: Mar 2024 --> Jul 2024
- | lodapolimab (LY3300054) / Eli Lilly
Phase classification, Trial completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Dec 6, 2023
P1, N=215, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Mar 2024 --> Jul 2024 Phase classification: P1a/1b --> P1 | Trial completion date: Dec 2023 --> Mar 2024
- | LY3200882 / Eli Lilly
Trial completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Oct 23, 2023
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Phase classification: P1a/1b --> P1 | Trial completion date: Dec 2023 --> Mar 2024 Trial completion date: Aug 2023 --> Aug 2024
- ||| LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Trial completion, Trial completion date, Combination therapy, Metastases: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - Oct 17, 2023
P1a/1b, N=209, Completed, Sponsor: Eli Lilly and Company
Trial completion date: Aug 2023 --> Aug 2024 Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2023
- Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort. (Available On Demand; Poster Bd # 469) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1274;
This retrospective analysis suggests that ICIs are effective and well tolerated in pts with MSI/dMMR advanced PDAC. Hence, our work supports the use of PD-1 inhibition in this group of pts with high unmet medical need.
- | lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Nov 23, 2022
P1a/1b, N=215, Active, not recruiting, Sponsor: Eli Lilly and Company
Hence, our work supports the use of PD-1 inhibition in this group of pts with high unmet medical need. Trial completion date: Dec 2022 --> Dec 2023
- | LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - Nov 22, 2022
P1a/1b, N=275, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Dec 2023
- | LY3200882 / Eli Lilly
Trial completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Sep 21, 2022
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Aug 2023
- || LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Clinical, Journal, Combination therapy, Monotherapy, Mismatch repair, Microsatellite instability: Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors. (Pubmed Central) - Apr 8, 2022
Both regimens showed promising clinical activity against PD-1/PD-L1 inhibitor-naïve MSI-H/dMMR tumors. The combination had limited clinical benefit in patients with PD-1/PD-L1 inhibitor-resistant/refractory MSI‑H/dMMR tumors.
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Clinical, P1 data, Journal, Combination therapy, Monotherapy: A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. (Pubmed Central) - Mar 23, 2022
These preliminary data suggest an alternative dose level of LY3381916 is needed for the combination with PD-L1 inhibitor. The combination clinical activity was limited in this study.
- || Clinical, P1 data, Journal, Monotherapy: Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial. (Pubmed Central) - Feb 11, 2022
P1a/1b
Lead-in abemaciclib before combining with LY3300054 was not feasible due to hepatotoxicity. Durable clinical benefits were seen in all regimens.
- | lodapolimab (LY3300054) / Eli Lilly
Journal: An Insight of RuBisCO Evolution through a Multilevel Approach. (Pubmed Central) - Jan 20, 2022
Thus, the cross-correlation dynamics analysis showed changes in the direction of movement of the secondary structures in the three isoforms. Finally, key amino acid residues related to the flexibility of the RuBisCO structure were indicated, providing important information for its enzymatic engineering.
- || LY3200882 / Eli Lilly
Clinical, P1 data, Journal: First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer. (Pubmed Central) - Jan 15, 2022
P1
LY3200882 as monotherapy and combination therapy was safe and well tolerated with preliminary antitumor activity observed in PC. Further studies to evaluate the efficacy of LY3200882 with gemcitabine and nab-paclitaxel in advanced PC are warranted.
- || prexasertib (LY2606368) / Eli Lilly, SOM Biotech, Ewha Womans University, lodapolimab (LY3300054) / Eli Lilly
Clinical, Journal: Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. (Pubmed Central) - Oct 1, 2021
P1
Further studies to evaluate the efficacy of LY3200882 with gemcitabine and nab-paclitaxel in advanced PC are warranted. Prexasertib in combination with PD-L1 blockade was tolerable and demonstrated preliminary activity in CCNE1-amplified HGSOC with evidence of cytotoxic T-cell activation in patient blood samples.
- | LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - Sep 5, 2021
P1a/1b, N=275, Active, not recruiting, Sponsor: Eli Lilly and Company
Prexasertib in combination with PD-L1 blockade was tolerable and demonstrated preliminary activity in CCNE1-amplified HGSOC with evidence of cytotoxic T-cell activation in patient blood samples. Trial completion date: Dec 2021 --> Dec 2022
- | LY3200882 / Eli Lilly
Trial completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Aug 18, 2021
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2021 --> Dec 2022 Trial completion date: Sep 2021 --> Dec 2022
- | lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Jul 16, 2021
P1a/1b, N=215, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Sep 2021 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022
- || prexasertib (ACR-368) / Acrivon Therap, lodapolimab (LY3300054) / Eli Lilly
Trial completion, Trial completion date, IO biomarker, Metastases: A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 10, 2021
P1, N=17, Completed, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Dec 2021 --> Dec 2022 Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Feb 2021
- | LY3200882 / Eli Lilly
Trial completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Aug 19, 2020
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Feb 2021 Trial completion date: Dec 2020 --> Sep 2021
- | LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - Aug 19, 2020
P1a/1b, N=275, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2020 --> Sep 2021 Trial completion date: Dec 2020 --> Dec 2021
- || lodapolimab (LY3300054) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Jul 17, 2020
P1a/1b, N=215, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting
- lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment change, Trial termination, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Jun 4, 2020
P1a/1b, N=60, Terminated, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting N=175 --> 60 | Active, not recruiting --> Terminated; Study terminated due to strategic business decision by Eli Lilly and Company.
- | LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - May 5, 2020
P1a/1b, N=275, Active, not recruiting, Sponsor: Eli Lilly and Company
N=175 --> 60 | Active, not recruiting --> Terminated; Study terminated due to strategic business decision by Eli Lilly and Company. Trial completion date: Jun 2020 --> Dec 2020
- || LY3200882 / Eli Lilly
Trial primary completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Mar 20, 2020
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2020 --> Dec 2020 Trial primary completion date: Jul 2020 --> Feb 2020
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Feb 21, 2020
P1a/1b, N=175, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2020 --> Feb 2020 Recruiting --> Active, not recruiting | Trial completion date: Feb 2022 --> May 2020 | Trial primary completion date: Jun 2021 --> Feb 2020
- || lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Feb 5, 2020
P1a/1b, N=215, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial completion date: Feb 2022 --> May 2020 | Trial primary completion date: Jun 2021 --> Feb 2020 Trial completion date: Apr 2022 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Jun 2020
- || LY3200882 / Eli Lilly
Enrollment closed: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Feb 5, 2020
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Apr 2022 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Jun 2020 Recruiting --> Active, not recruiting
- || LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - Feb 5, 2020
P1a/1b, N=275, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=196 --> 275 | Trial completion date: Jun 2021 --> Jun 2020 | Trial primary completion date: Jun 2021 --> Dec 2019
- || prexasertib (ACR-368) / Acrivon Therap, lodapolimab (LY3300054) / Eli Lilly
Enrollment closed, Enrollment change, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 5, 2020
P1, N=17, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=196 --> 275 | Trial completion date: Jun 2021 --> Jun 2020 | Trial primary completion date: Jun 2021 --> Dec 2019 Recruiting --> Active, not recruiting | N=28 --> 17
- | LY3300054 / Eli Lilly
Preclinical, Journal, IO Complimentary Diagnostic: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. (Pubmed Central) - Feb 1, 2020
Recruiting --> Active, not recruiting | N=28 --> 17 LY3300054 is currently being evaluated in phase I clinical trials for oncology indications.
- LY3300054 / Eli Lilly, LY3381916 / Eli Lilly
A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer (Room B) - Oct 29, 2019 - Abstract #ESMOIO2019ESMO_IO_292;
P1a/1b
The 240mg dose QD is the RP2D for combination with PD-L1 in expansion cohorts.Legal entity responsible for the study: Eli Lilly and Company. Funding: Eli Lilly and Company.
- prexasertib (LY2606368) / Eli Lilly, Pfizer, LY3300054 / Eli Lilly
Phase 1 combination study of the CHK1 inhibitor prexasertib (LY2606368) and anti-PD-L1 antibody LY3300054, in patients with high-grade serous ovarian cancer and other advanced solid tumors (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_753;
An expansion cohort in this population is currently being enrolled utilizing schedule B. Comprehensive characterization of the immune microenvironment will be performed in paired tumor biopsies, with attention to pharmacodynamic proof-of-mechanism endpoints, including T cell infiltration and PD-L1 expression and their correlation with the induction of DNA damage. Additionally, immune signatures will be correlated with genomic profile and response duration.
- LY3300054 / Eli Lilly
The positive correlation between baseline absolute eosinophil count (AEC) in blood and clinical benefit to PD-(L)1 inhibition monotherapy (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_731;
Additionally, immune signatures will be correlated with genomic profile and response duration. LY3300054 was well-tolerated and demonstrated antitumor activity in patients with MSI-H solid tumors; combination expansions are ongoing.
- | lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment change, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Sep 11, 2019
P1a/1b, N=175, Recruiting, Sponsor: Eli Lilly and Company
LY3300054 was well-tolerated and demonstrated antitumor activity in patients with MSI-H solid tumors; combination expansions are ongoing. N=290 --> 175
- | lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Aug 18, 2019
P1a/1b, N=215, Recruiting, Sponsor: Eli Lilly and Company
N=290 --> 175 Trial completion date: Jul 2021 --> Apr 2022 | Trial primary completion date: Jan 2020 --> Oct 2020
- || LY3200882 / Eli Lilly
Trial completion date, Trial primary completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Jun 5, 2019
P1, N=223, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jul 2021 --> Apr 2022 | Trial primary completion date: Jan 2020 --> Oct 2020 Trial completion date: May 2021 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Jul 2020
- || LY3321367 / Eli Lilly, lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (clinicaltrials.gov) - Jun 5, 2019
P1a/1b, N=196, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: May 2021 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Jul 2020 Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- || lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Apr 3, 2019
P1a/1b, N=215, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jan 2020
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Trial initiation date, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Apr 3, 2019
P1a/1b, N=290, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jan 2020 Initiation date: Nov 2017 --> Feb 2018
- || lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Mar 5, 2019
P1a/1b, N=290, Recruiting, Sponsor: Eli Lilly and Company
Initiation date: Nov 2017 --> Feb 2018 Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Sep 2019 --> Jun 2021
- | prexasertib (ACR-368) / Acrivon Therap, lodapolimab (LY3300054) / Eli Lilly
New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 19, 2019
P1, N=28, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | lodapolimab (LY3300054) / Eli Lilly
Enrollment change, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Aug 23, 2018
P1a/1b, N=215, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Sep 2019 --> Jun 2021 N=115 --> 215
- | LY3200882 / Eli Lilly
Enrollment change: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Jul 19, 2018
P1, N=199, Recruiting, Sponsor: Eli Lilly and Company
N=115 --> 215 N=149 --> 199
- || LY3200882 / Eli Lilly
Trial completion date, Trial primary completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Jun 11, 2018
P1, N=149, Recruiting, Sponsor: Eli Lilly and Company
N=149 --> 199 Trial completion date: Apr 2020 --> May 2021 | Trial primary completion date: Oct 2019 --> Jun 2019
- || lodapolimab (LY3300054) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Apr 17, 2018
P1a/1b, N=115, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Apr 2020 --> May 2021 | Trial primary completion date: Oct 2019 --> Jun 2019 Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020
- ||| lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
Enrollment open, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Dec 4, 2017
P1a/1b, N=290, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020 Not yet recruiting --> Recruiting
- ||| lodapolimab (LY3300054) / Eli Lilly, LY3381916 / Eli Lilly
New P1 trial, Combination therapy: A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (clinicaltrials.gov) - Nov 17, 2017
P1a/1b, N=290, Not yet recruiting, Sponsor: Eli Lilly and Company
- || lodapolimab (LY3300054) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Oct 7, 2017
P1a/1b, N=100, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2018 --> Jul 2019